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Trials: Learning which Subpopulations Benefit from
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1 Abstract
We consider the problem of designing a randomized trial for comparing two treatments ver-
sus a common control in two disjoint subpopulations. The subpopulations could be defined
in terms of a biomarker or disease severity measured at baseline. The goal is to determine
which treatments benefit which subpopulations. We develop a new class of adaptive en-
richment designs tailored to solving this problem. Adaptive enrichment designs involve a
preplanned rule for modifying enrollment based on accruing data in an ongoing trial. The
proposed designs have preplanned rules for stopping accrual of treatment by subpopulation
combinations, either for efficacy or futility. The motivation for this adaptive feature is that
interim data may indicate that a subpopulation, such as those with lower disease severity
at baseline, is unlikely to benefit from a particular treatment while uncertainty remains for
the other treatment and/or subpopulation. We optimize these adaptive designs to have the
minimum expected sample size under power and Type I error constraints. We compare
1
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the performance of the optimized adaptive design versus an optimized non-adaptive (single
stage) design. Our approach is demonstrated in simulation studies that mimic features of a
completed trial of a medical device for treating heart failure. The optimized adaptive design
has 25% smaller expected sample size compared to the optimized non-adaptive design; how-
ever, the cost is that the optimized adaptive design has 8% greater maximum sample size.
Open-source software that implements the trial design optimization is provided, allowing
users to investigate the tradeoffs in using the proposed adaptive versus standard designs.
Keywords: Randomized Clinical Trial, Treatment Effect Heterogeneity
2 Introduction
Our trial design problem is motivated by the SMART-AV trial (Ellenbogen et al., 2010),
a phase 4 randomized trial of patients with medically-refractive heart failure with severe
left ventricular systolic dysfunction. All the participants had an implanted cardiac resyn-
chronization therapy defibrillator. The trial aimed to investigate the effect of optimizing
the atrioventricular (AV) delay in this medical device. Two methods of optimizing the atri-
oventricular delay (called treatments) were compared to a fixed delay of 120 milliseconds
(called control). No statistically significant differences were found between the treatments
and control, for the primary outcome of left ventricular end-systolic volume.
Previous scientific knowledge had indicated that participants with short QRS duration,
defined as QRS ≤ 150 milliseconds, may be more likely to benefit from the treatments (Stein
et al., 2010). This raises the question of whether a design targeted to identify treatment
effects in subpopulations defined by QRS duration could have been more informative. To
address this question, we develop and evaluate a new class of adaptive enrichment designs
comparing two treatments to a common control in two disjoint subpopulations.
Adaptive enrichment designs have a preplanned rule for modifying enrollment criteria
2
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based on accruing data in an ongoing trial (Wang et al., 2009). The proposed designs can stop
accrual of treatment by subpopulation combinations for either efficacy or futility at the end
of each stage. We compare the performance of these adaptive designs versus standard designs
in determining which treatment by subpopulation combinations lead to improved outcomes.
Our proposed class of adaptive enrichment designs uses a multiple testing procedure that
combines advantageous features from the methods of Dunnett (1955), Maurer and Bretz
(2013), and Rosenblum et al. (2016).
The proposed adaptive designs have the following properties: they leverage correlations
between treatment effect estimators that share a common control; they allow for continued
accrual of remaining treatments/subpopulations after some null hypotheses are rejected in
order to continue testing the remaining null hypotheses; they improve power by lowering
the rejection threshold for the remaining null hypotheses after a null hypothesis has been
rejected; they strongly control the familywise Type I error rate, asymptotically; the multiple
testing procedure is a function of only minimal sufficient statistics, and therefore avoids
power losses that can affect some adaptive designs as described by Emerson (2006). We use
non-binding futility boundaries, which are generally preferred by the U.S. Food and Drug
Administration (Liu and Anderson, 2008).
We optimize the multiple testing procedure and enrollment modification rule in order to
minimize expected sample size while satisfying power and Type I error constraints. As there
is no known optimization procedure that is guaranteed to converge to the global optimum
solution, we use simulated annealing, a general purpose optimization method. Fisher and
Rosenblum (ress) used simulated annealing to optimize over a class of designs evaluating the
effectiveness of a single treatment in two subpopulations. Our setting differs since it involves
two treatments versus control, a different class of adaptive designs, a different set of null
hypotheses, and a more complex set of power requirements.
Others have proposed adaptive designs for multi-arm trials for the overall population (but
3
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not considering subpopulations). Magirr et al. (2012) generalized the method of Dunnett
(1955) to such trials and show how to compute sample sizes under power constraints for the
least favorable configuration of treatment effects. Wason and Jaki (2012) used simulated
annealing to search for the efficacy boundaries that minimize expected sample size for trials
with multiple arms and stages. In both of the aforementioned references, the trial is stopped
when the first null hypothesis is rejected, unlike our approach. Several designs, e.g., Thall
et al. (1988); Kelly et al. (2005), have been proposed that pick only one treatment at the
interim analysis to continue to the later stages. Stallard and Friede (2008) proposed an
adaptive design with treatment selection at an interim analysis, but the number of treatments
allowed to continue after each stage must be prespecified. In contrast, our designs do not
a priori restrict how many treatment by subpopulation combinations will continue to later
stages. Posch et al. (2005), Koenig et al. (2008), and Bretz et al. (2010) propose adaptive
designs based on the p-value combination or conditional error function approaches; these
approaches allow more flexibility in the adaptation rule than those considered here, but at
the cost of not using data only through minimal sufficient statistics, which can lead to power
loss.
Urach and Posch (2016) optimize multi-arm, group sequential designs. Their designs
differ from ours in that they only consider the overall population, use a different form of effi-
cacy boundaries, and do not reallocate alpha between null hypotheses to improve power. The
search space of the optimization problem of Urach and Posch (2016) is substantially smaller
than ours. For example, Urach and Posch (2016) optimize over at most five parameters but
the optimized design presented in Section 6.3 involves over 24 parameters.
Section 3 describes the data structure, null hypotheses, and statistics. The proposed
class of adaptive enrichment designs is defined in Section 4. Section 5 defines the trial design
optimization problem. A simulation study that mimics features of the SMART-AV trial is
used to compare performance of optimized adaptive versus standard designs, in Section 6.
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The open-source software implementing our trial design optimization, which has a graphical
user-interface that runs on a web-browser, is described in Section 7. Directions for future
research are discussed in Section 8.
3 Problem Setup
3.1 Data Structure and Null Hypotheses
We are interested in comparing two treatments versus a common control in two disjoint
subpopulations that partition the overall population. Subpopulations must be defined by
measurements made before randomization, and this definition must be prespecified in the
study protocol. In our motivating example, these subpopulations consist of patients with
QRS ≤ 150ms (short QRS) and those with QRS > 150ms (long QRS).
Throughout, the subscript a ∈ {0, 1, 2} denotes the study arm, s ∈ {1, 2} denotes the
subpopulation, and k ≤ K denotes the stage of the trial. Let pis denote the proportion
of the combined population in subpopulation s ∈ {1, 2}. We assume these proportions are
known and pi1 + pi2 = 1. Let µa,s denote the mean outcome under assignment to study arm
a ∈ {0, 1, 2} for subpopulation s ∈ {1, 2}. We refer to arms a = 1, 2 as the treatment arms
and a = 0 as the control arm. The difference between the population mean of the outcome
under assignment to treatment a ∈ {1, 2} versus control for subpopulation s is defined as
δa,s = µa,s − µ0,s. Denote the vector of average treatment effects by δ = (δ1,1, δ2,1, δ1,2, δ2,2).
There are four null hypotheses of interest: Ha,s : δa,s ≤ 0, a ∈ {1, 2}, s ∈ {1, 2}, corre-
sponding to no average treatment benefit for each treatment by subpopulation combination.
Let σ2a,s, a ∈ {0, 1, 2}, s ∈ {1, 2} denote the variance of the primary outcome in study arm
by subpopulation combination (a, s).
5
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3.2 Sample Sizes Per Stage for Each Treatment by Subpopulation
Combination
Each participant is randomized to one of the two treatment arms or to the control arm, and
her/his arm assignment is never changed throughout the trial. In stage 1, both subpopu-
lations are enrolled and each participant is assigned with probability 1/3 to a study arm
a = 0, 1, 2. At the interim analysis after each stage, for each subpopulation, the preplanned
rule may decide to stop assigning new participants to one or both treatment arms a ∈ {1, 2}.
The decision can differ by subpopulation, e.g., subpopulation 1 may be stopped entirely
while subpopulation 2 continues enrollment and assignment to arms a = 0, 1.
Stopping accrual for a treatment by subpopulation combination (a, s) means that no
future participants enrolled from subpopulation s are assigned to arm a. If both treatment
arms a = 1, 2 have accrual stopped, then no more subpopulation s participants are en-
rolled. After stopping accrual of a treatment by subpopulation combination for futility, the
corresponding null hypothesis is no longer tested.
For any subpopulation and stage, if neither treatment arm a ∈ {1, 2} has been stopped
then the randomization ratio is 1:1:1 to each arm a ∈ {0, 1, 2}; if a single treatment arm
a ∈ {1, 2} has been stopped, then the randomization ratio is 1:1 to the other treatment
arm and control; if both treatment arms a = 1, 2 have been stopped, then the control arm
is stopped as well. This randomization method can be approximately achieved by block
randomization stratified by subpopulation.
A reason we use 1:1 randomization ratios is that different ratios at different stages could
lead to bias if the distribution of the primary outcome among subjects enrolled differs across
time. In a related setting, randomizing more participants to the common control arm has
been shown to lead only to minor power improvements (Wason et al., 2012). Also, a higher
allocation to the control arm might reduce the willingness of subjects to participate in the
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trial (Halpern et al., 2003).
The following design parameters need to be prespecified in the study protocol: the maxi-
mum number of stages K; the number of subpopulation s participants enrolled during stage
k assigned to arm a (denoted na,s,k), assuming enrollment has not been stopped for that
arm by subpopulation combination. Define nk =
∑2
a=0
∑2
s=1 na,s,k as the maximum num-
ber of participants that can be enrolled during stage k. By the above assumptions about
randomization ratios and the assumption that enrollment is uniform over time and propor-
tional to subpopulation size (which we assume throughout), we have na,s,k = pisnk/3 for each
a ∈ {0, 1, 2}, s ∈ {1, 2}, k ≤ K. Define the maximum sample size n = ∑Kk=1 nk, and the
vector of sample sizes N = (na,s,k : a = 0, 1, 2; s = 1, 2; k = 1, . . . , K). Complete prespec-
ification of the adaptive design is required by regulators such as the U.S. Food and Drug
Administration (FDA, 2010; FDA, 2016).
If no treatment arm has been stopped for subpopulation s at or before the end of stage
k − 1, then na,s,k = pisnk/3 newly enrolled participants from subpopulation s are assigned
to each arm a = 0, 1, 2 during stage k. If exactly one treatment arm a ∈ {1, 2} has been
stopped for subpopulation s ∈ {1, 2} at or before the end of stage k−1, then na,s,k = pisnk/3
newly enrolled participants from subpopulation s are assigned to the other treatment arm
(a′ = 3 − a) and to the control arm (for a total of 2pisnk/3 enrolled from subpopulation s)
during stage k.
The above rules ensure that the number enrolled during stage k for any arm by sub-
population combination (a, s) is either the prespecified na,s,k or 0. The impact is that the
statistics defined below have the canonical structure from Jennison and Turnbull (1999, Ch.
3.1), and so are asymptotically multivariate normal with mean vector and covariance matrix
that are straightforward to compute. This facilitates the computation of efficacy boundaries
in Section 4.2.
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3.3 Data Structure and Statistics
Let Si,k be a random variable taking values in {1, 2}, which indicates whether participant i
enrolled during stage k belongs to subpopulation 1 or 2. Let Ai,k ∈ {0, 1, 2} be the study arm
assignment of participant i at stage k. The outcome for participant i at stage k is denoted
by Yi,k, which can be continuous, binary, or integer valued. The data on participant i at
stage k in the trial consists of the vector (Si,k, Ai,k, Yi,k). We assume that conditioned on
(Si,k = s, Ai,k = a), the outcome Yi,k is an independent draw from an unknown distribution
Qa,s with mean µa,s and variance σ
2
a,s.
For each a ∈ {0, 1, 2}, s ∈ {1, 2}, k ∈ {1, . . . , K}, define Y¯a,s,k as the (cumulative) average
of all primary outcomes from study arm a and subpopulation s observed prior to analysis
k. The statistic used to test null hypothesis Ha,s at analysis k is the following standardized
difference between sample means of the outcome comparing treatment arm a versus control:
Za,s,k =
(
Y¯a,s,k − Y¯0,s,k
){ σ2a,s + σ20,s∑k
k′=1
∑nk′
i=1 I(Si,k′ = s, Ai,k′ = a)
}−1/2
, (1)
where I(X) is the indicator variable taking value 1 if X is true and 0 otherwise. If treatment
by subpopulation combination (a, s) is not enrolled through stage k, then Za,s,k is unde-
fined. We assume the joint distribution of the statistics Z = {Za,s,k : a = 1, 2; s = 1, 2; k =
1, . . . , K} has the canonical form of Jennison and Turnbull (1999, Chapter 3.1), which holds
asymptotically for many types of outcomes and statistics. This joint distribution is mul-
tivariate normal with mean and covariance matrix given in Supplementary Web Appendix
S.1.
For binary outcomes, the vector of statistics Z depends on the data only through minimal
sufficient statistics (Rosenblum et al., 2016); this also holds for normally distributed outcomes
if the variance terms in the display above are replaced by sample variances. The decision rules
for the adaptive enrichment design below depend only on the data through these statistics.
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It is therefore exempt from the criticism of some adaptive designs that test statistics are not
a function of minimal sufficient statistics (Emerson, 2006).
When outcomes are measured with delay, some participants may be enrolled but not yet
have their outcomes observed at an interim analysis. These participants do not contribute
to the statistics at that analysis, but they do count toward the sample size enrolled (which
is important since our goal is to minimize expected sample size).
4 Adaptive Enrichment Designs
4.1 Overview
We describe our proposed class of adaptive enrichment designs, denoted by DADAPT . Each
such design consists of a multiple testing procedure for the four null hypotheses Ha,s, a =
1, 2, s = 1, 2, and an enrollment modification rule. The enrollment modification rule has
the following form: for each subpopulation, enrollment continues until both treatment arms
(a = 1, 2) in that subpopulation have been stopped. Stopping can be for efficacy or futility,
and can only occur at the analysis following each stage. The multiple testing procedure
defined below involves efficacy and futility boundaries on the z-scale, and is designed to ensure
strong control of the familywise Type I error rate, asymptotically. We next describe the
construction of efficacy boundaries, followed by how they are applied to determine whether
to stop each treatment by subpopulation combination for efficacy at each analysis.
4.2 Efficacy and Futility Boundaries
Efficacy boundaries, denoted (us,k, zs,k), are constructed using an error spending approach
(Lan and DeMets, 1983). Let α denote the desired familywise Type I error rate, e.g., α =
0.05. Let αs,k > 0, s ∈ {1, 2}, 1 ≤ k ≤ K denote the prespecified alpha allocation associated
9
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with each subpopulation s at stage k. These are required to satisfy
∑2
s=1
∑K
k=1 αs,k = α. The
value of each αs,k (along with other design parameters) will be determined using optimization
as described in Section 5. There is no treatment-specific subscript a in the alpha allocations
αs,k since for each subpopulation s and stage k, the efficacy boundaries for rejecting Ha,s are
the same for each a ∈ {1, 2}.
For each subpopulation s ∈ {1, 2}, we compute the efficacy boundaries {(us,k, zs,k) : k =
1, . . . , K} sequentially. For stage k = 1, (us,1, zs,1) are the solutions to
P0 {max(Z1,s,1, Z2,s,1) > us,1} = αs,1 and P0(Z1,s,1 > zs,1) = αs,1,
where P0 denotes the global null hypothesis δ = (0, 0, 0, 0) of zero average treatment effect
for every treatment by subpopulation combination, which implies each Za,s,k has mean 0.
At the end of each stage k > 1, (us,1, zs,1) . . . , (us,k−1, zs,k−1) have already been calculated
and zs,k is calculated by finding the smallest value zs,k satisfying
P0(Z1,s,k′ ≤ zs,k′ for all k′ < k, and Z1,s,k > zs,k) ≤ αs,k, (2)
and then us,k is calculated by finding the minimum value us,k ∈ [zs,k,∞) such that
P0
{
max(Z1,s,k′ , Z2,s,k′) ≤ us,k′ for all k′ < k, and max(Z1,s,k, Z2,s,k) > us,k
}
≤ αs,k. (3)
The efficacy boundaries zs,k, k = 1, . . . , K could equivalently be calculated using treatment
a = 2 instead of treatment a = 1, which follows from the canonical covariance structure of
the statistics Za,s,k given in the Supplementary Web Appendix S.1 and the 1:1 randomization
ratio between each treatment and control arm. The probability in (2) involves the covariance
structure among statistics for the same treatment and subpopulation but at different stages.
The probability in (3) uses the correlation among statistics for the same subpopulation but
10
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different treatment arms and stages.
We use alpha reallocation to improve power at the last stage K for a subpopulation if the
null hypotheses corresponding to both treatments a = 1, 2 for the other subpopulation have
been rejected. For any subpopulation s′ ∈ {1, 2}, if both H1,s′ , H2,s′ have been rejected at or
before final analysis K, then we recompute both zs,K and us,K for the other subpopulation
s 6= s′ by replacing αs,K on the right sides of (2) and (3) by αs,K +
∑K
k=1 αs′,k. Denote the
updated values by z˜s,K and u˜s,K . Each is less or equal to the corresponding value without
the alpha reallocation.
Probabilities that involve multivariate normal distributions such as those appearing in
equations (2) and (3) can quickly and reliably be calculated using the R package mvtnorm
(Genz et al., 2017). Binary search can then be used to calculate the smallest efficacy bound-
aries satisfying inequalities (2) and (3).
The futility boundaries F = (fa,s,k ∈ R : a = 1, 2; s = 1, 2; k ≤ K − 1) are unrestricted
and, like the alpha allocations αs,k, will be optimized as described in Section 5.
4.3 Class of Adaptive Enrichment Designs
A generic adaptive enrichment design in the class DADAPT is denoted by D = (K, E ,F ,N ),
and consists of the following design parameters (which are specified before the trial starts):
the maximum number of stages K, the alpha allocations E = (αs,k : s = 1, 2; k ≤ K), the
futility boundaries F , and the sample sizes N . We next define the enrollment modification
rule and multiple testing procedure for each D ∈ DADAPT . At the analysis taking place at
the end of each stage k ≤ K, for each subpopulation s ∈ {1, 2} where at least one treatment
arm continued accrual through stage k, the following sequence of actions is taken:
1. If exactly one treatment arm a ∈ {1, 2} had accrual stopped for subpopulation s at
a previous analysis k′ < k, then do the following: If treatment arm a ∈ {1, 2} was
11
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previously stopped for efficacy in subpopulation s and Za′,s,k ≥ zs,k for the other
treatment arm a′ = 3 − a, then reject Ha′,s. Otherwise, if treatment arm a was
previously stopped for futility in subpopulation s and Za′,s,k ≥ us,k for a′ = 3−a, then
reject Ha′,s.
2. If neither treatment arm a = 1, 2 had accrual stopped for subpopulation s at a previous
analysis k′ < k: If both max(Z1,s,k, Z2,s,k) ≥ us,k and min(Z1,s,k, Z2,s,k) ≥ zs,k, then re-
ject both subpopulation s null hypotheses H1,s, H2,s. Otherwise, if max(Z1,s,k, Z2,s,k) ≥
us,k, then reject the null hypothesis Ha,s corresponding to the larger statistic.
3. For each null hypothesis Ha,s rejected in (1) or (2), accrual for the corresponding
treatment by subpopulation combination (a, s) is stopped for efficacy. For each null
hypothesis Ha,s that has not been rejected, the corresponding treatment by subpopu-
lation combination (a, s) has accrual stopped for futility if Za,s,k ≤ fa,s,k.
4. If accrual for both treatment arms a ∈ {1, 2} in subpopulation s are stopped (either
for efficacy or futility) or k = K, then stop all accrual of subpopulation s. Otherwise,
continue subpopulation s accrual in the next stage with random assignment to the
arms a ∈ {0, 1, 2} that have not been stopped.
The trial continues until every treatment by subpopulation combination is stopped for
efficacy/futility or the final analysis K is reached. If the trial continues to the end of
stage K, then the following extra step is conducted (after conducting steps 1-4 above for
each subpopulation at analysis K): If both null hypotheses for a subpopulation s′ ∈ {1, 2}
were rejected at or before analysis K, then the efficacy thresholds (us,K , zs,K) are replaced
by (u˜s,K , z˜s,K) for the other subpopulation s 6= s′ and steps 1-4 are conducted again for
subpopulation s. This extra step can only improve power or leave it unchanged since each
of u˜s,K , z˜s,K is less or equal to the corresponding efficacy boundary without the tilde.
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Rejecting any null hypothesis implies that the null hypothesis is rejected at all future
stages. For any subpopulation s ∈ {1, 2} and stage k ≤ K, only one of steps 1 and 2 can
be applied (depending on which treatment by subpopulation combinations were stopped at
previous analyses). The above procedure leads to the same decisions regardless of whether
1-4 are applied first to subpopulation s = 1 or s = 2. The above steps can be applied in the
special case of a single stage design (K = 1), where only the multiple testing procedure is
used.
The above multiple testing procedure incorporates features from previous work. Dunnett
(1955) uses tests based on the maximum of different statistics to control the familywise
Type I error rate, as we do in (3). Maurer and Bretz (2013) and Rosenblum et al. (2016)
reallocate alpha from rejected null hypotheses to the remaining null hypotheses, leading to
lower rejection thresholds and greater power. Our procedure does this through the lower
rejection thresholds z˜s,K and u˜s,K . The way that we combine the above features to construct
the multiple testing procedure and enrollment modification rule in 1-4 above, is tailored to
our specific trial design problem.
4.4 Familywise Type I Error Rate
Control of the familywise Type I error rate at level α means that the probability of rejecting
at least one true null hypothesis is at most α. Strong control means that this holds for any
mean treatment effect vector δ ∈ R4. We assume non-binding futility boundaries (Liu and
Anderson, 2008), i.e., we require the familywise Type I error rate to be strongly controlled
even if futility boundaries are ignored. The following theorem is proved in the Supplementary
Web Appendix:
Theorem 4.1. For any K ≥ 1, sample sizes N satisfying the assumptions in Section 3.2,
futility boundaries F , and positive-valued αs,k that sum to α, the corresponding adaptive
13
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enrichment design D ∈ DADAPT strongly controls the familywise Type I error rate at level
α, asymptotically.
5 Trial Design Optimization: Search Space, Objective
Function, and Optimization Method
5.1 Optimization Problem
Let θ = (µa,s, σ
2
a,s, pis : a = 0, 1, 2; s = 1, 2) denote the population parameters. The joint
distribution of statistics Z is determined by the population parameters θ and design param-
eters D. For given θ, D, let ESS(θ, D) denote the expected sample size for design D under
population parameters θ. The expectation is with respect to the distribution on Z induced
by θ and D.
We next define our optimization goal, called the objective function, which maps each
design D to a real value (with smaller values being more desirable). The objective function
is defined as ESSΛ(D) =
∫
θ
ESS(θ, D)dΛ(θ), where Λ is a distribution on the population
parameters θ. An example of Λ that consists of a discrete set of point masses on scenarios of
interest is given in Section 6. Our optimization problem is formulated in the decision theory
framework and the only role of Λ is in defining the objective function.
The optimization problem is to search for the design D ∈ DADAPT that minimizes ex-
pected sample size ESSΛ(D) under prespecified power constraints. (By Theorem 4.1, all
designs D ∈ DADAPT are guaranteed to strongly control the asymptotic, familywise Type I
error rate.) The power constraints in our problem consist of M scenarios, i.e., population
parameter vectors denoted θ(1), . . . ,θ(M). These are chosen by the clinical investigator to
represent scenarios of interest. The power constraints corresponding to each scenario θ(m)
are that for each pair (a, s) : a ∈ {1, 2}, s ∈ {1, 2} for which the average treatment effect
14
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δ
(m)
a,s = µ
(m)
a,s − µ(m)0,s is at least the minimum, clinically meaningful level denoted δmin, the
power to reject Ha,s must be at least 80%. We let POW(θ
(m), D, a, s) denote the probability
that the design D rejects (at least) null hypothesis Ha,s when data are generated according
to the population parameter vector θ(m).
The search space for our optimization problem is all designs D ∈ DADAPT that have
at most K ≤ 4 stages. We restricted to at most 4 stages since there were diminishing
improvements as the number of stages was increased from 2 to 4. Larger numbers of stages
lead to both a larger search space and more challenging computations in evaluating the
objective function.
5.2 Optimization Method
To search for the optimal design, we use a general purpose optimization algorithm called
simulated annealing (SA). While it is not guaranteed to find the global optimum solution,
which is an open research question for our problem, it may find adaptive designs with
improved performance compared to standard designs, which is our goal.
SA iteratively proposes a new candidate vector D′ of design parameters by randomly
perturbing the current candidate design parameters D. The new design D′ is accepted as
a replacement if it is superior to the current design D in terms of a composite performance
score V (D) defined below that combines the objective function (expected sample size) with
penalty terms to account for the power constraints. If the candidate is not superior, it may
still be accepted with some probability. By occasionally accepting less optimal candidates,
this allows the potential to escape a local minimum. The performance and evolution of
the algorithm are controlled by a cooling schedule, which determines the rate at which
suboptimal candidate designs are accepted and how new candidates are generated. We use
the optim function in R which implements the simluated annealing algorithm described in
Be´lisle (1992).
15
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Each candidate design D is evaluated by the SA algorithm in terms of the objective
function ESSΛ(D) and how well it satisfies the power constraints. A composite performance
score V (D) is computed by combining these as follows:
V (D) = ESSΛ(D) + λ
M∑
m=1
∑
a,s
I
(
δ(m)a,s ≥ δmin
){
0.8− POW(θ(m), D, a, s)
}
+
,
where (x)+ = max(x, 0) and λ is a positive constant that sets the penalty for failing to
achieve the power constraints. The terms on the right side of the above display penalize for
violation of the power constraints, with the penalty proportional to how far the actual power
is from the desired 80% power. The term I(δ
(m)
a,s ≥ δmin) is the indicator of the treatment
effect for treatment by subpopulation combination (a, s) exceeding the minimum, clinically
meaningful level in scenario θ(m); this term is included since we only require power to be at
least 80% when that condition holds. If all power constraints are satisfied by D then the
term on the right is 0 and all that remains is the expected sample size ESSΛ(D). We set
λ = 106 in our optimization in the next section.
The lengths of the futility boundary and alpha-allocation vectors increase with the num-
ber of stages. As a consequence, the dimension of the search space increases with the number
of stages. For this reason, we keep the number of stages K fixed for each run of the simulated
annealing algorithm. For each K ∈ {2, 3, 4}, we ran 200 parallel versions of the simulated
annealing algorithm with each version using 500 iterations. All parameters in the search
space are restricted to fall within their required domains, e.g., each αs,k and nk must be
positive and the αs,k must sum to α. In addition, we restrict all interim analyses to occur
between when 10% and 90% of the primary outcomes are observed.
Calculating expected sample size and power requires integrating over multivariate normal
distributions. We approximate each such integral by 50,000 Monte Carlo draws from the
corresponding multivariate normal distribution.
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6 Application to the SMART-AV Trial
6.1 Optimization Problem Definition
The primary outcome in the SMART-AV trial was the six month change in left ventricular
end-systolic volume (in ml), which is measured six months after enrollment. Subpopulations
1 and 2 are defined as those with short and long QRS, respectively. We set the accrual rate
to 20 participants per month. The familywise Type I error rate is set to be α = 0.05.
In the SMART-AV trial, the proportion of participants with short QRS was 49% and the
outcome standard deviation was assumed to be 60ml. We mimic these by setting pi1 = 0.49
and σa,s = 60 for each a ∈ {0, 1, 2}, s ∈ {1, 2} throughout. Given these values, the joint
distribution of statistics Z depends on the population parameters θ only through the average
treatment effects δ = (δ1,1, δ2,1, δ1,2, δ2,2) where δa,s = µa,s − µ0,s. Therefore, it suffices to
define the distribution Λ (used in the objective function) and power constraint scenarios
θ(1), . . . ,θ(M) in terms of δ rather than the full vector θ.
The minimum clinically meaningful treatment effect used for powering the SMART-AV
trial was δmin = 15ml. We use this in our definition of Λ, which is defined to be the
equally weighted mixture of the following six scenarios (each with a point mass at a specific
value of δ): δ(1) = (0, 0, 0, 0); δ(2) = (15, 0, 0, 0); δ(3) = (15, 15, 0, 0); δ(4) = (15, 0, 15, 0);
δ(5) = (15, 15, 15, 0); δ(6) = (15, 15, 15, 15). Scenario 1 represents the global null hypothesis
of no average effect for every treatment by subpopulation combination. Scenario 6 represents
a benefit of 15ml for each treatment by subpopulation combination. The other scenarios
involve benefits of some treatments for some subpopulations.
The distribution Λ is asymmetric in that there is a positive treatment effect in subpop-
ulation 2 (long QRS) only when there is also a positive treatment effect in subpopulation
1 (short QRS). It is here that we incorporated the prior scientific knowledge that the short
QRS subpopulation is more likely to benefit from treatment. Analogously, we incorporated
17
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that treatment 2 is expected to benefit a subpopulation (compared to control) only when
the same holds for treatment 1.
We use the same six vectors δ(1), . . . , δ(6) above to define the power constraints. This
means that in each scenario 1-6, for each treatment arm a ∈ {1, 2} by subpopulation s ∈
{1, 2} combination where the corresponding treatment effect δa,s ≥ 15ml, we require at
least 80% power to reject Ha,s. For example, consider the null hypothesis H1,1; the power
constraints are that in each scenario 2-6, the power to reject (at least) H1,1 is at least 80%.
6.2 Classes of Designs Compared
We describe four subclasses of the designs DADAPT , in increasing order of complexity. In
Section 6.3, we solve the optimization problem for each class and compare the resulting four
optimized designs in terms of expected and maximum sample sizes.
The first design class, called simple 1-stage designs, has a single stage K = 1 with equal
α allocation between the two subpopulations, i.e. each αs,1 = α/2. The sample size n is
optimized to be the smallest such that the power and Type I error constraints are all satisfied.
The second design class, called optimized 1-stage designs, has a single stage where the
α allocation between the two subpopulations is optimized. That is, simulated annealing is
used to search for the smallest sample size n such that there exists a pair (α1,1, α2,1) for
which the power and Type I error constraints are satisfied.
The third design class, called simple adaptive designs, optimizes over the number of stages
K ∈ {2, 3, 4} and the maximum sample size n, but the following are set (not optimized):
the alpha allocation is set to be equally partitioned (αs,k = α/(2K) for s = 1, 2; k ≤ K),
analysis times are equally spaced in terms of the number of observed outcomes, and all
futility boundaries are set to zero.
The fourth design class, called optimized adaptive designs, is just as the third class except
the alpha allocation, analysis timing, and futility boundaries are optimized.
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The reason we use the term “adaptive” only for the third and fourth classes of designs is
that 1-stage designs do not involve any adaptations. We refer to the optimized design from
each class above as the simple 1-stage design, optimized 1-stage design, simple adaptive
design, and optimized adaptive design, respectively. The simulated annealing algorithm
requires initial values to be input for all design parameters that it optimizes. These are
given in Supplementary Web Appendix S.2.
6.3 Results
The rightmost 2 columns of Table 1 show the expected and maximum sample sizes for the
optimal design in each of the four classes. The optimized adaptive design has 25% smaller
expected sample size compared to the optimized 1-stage design. However, the cost is that the
optimized adaptive design has 8% greater maximum sample size than the optimized 1-stage
design.
The optimized adaptive design has substantially lower expected and maximum sample
size compared to the simple adaptive design. This shows the importance of optimizing the
alpha allocation, analysis timing, and futility boundaries for the adaptive designs.
Columns 3-6 of Table 1 show design parameters from each of the four designs. The only
free parameter in the simple 1-stage design was the sample size n, whose optimized value is
1818. For the optimized 1-stage design, the proportion of alpha allocated to subpopulation
one is 54%. This only slightly differs from the simple 1-stage design, which allocates 50%
of alpha to each subpopulation. This minor improvement over the simple 1-stage design
produced only a small sample size reduction (from 1818 to 1779).
The analyses for the optimized adaptive design occur when 39%, 63%, 70%, and 100%
of the primary outcomes are observed. For scenarios 1-6, the expected sample sizes for the
optimized adaptive design are 1234, 1273, 1381, 1284, 1395, and 1477, respectively. Their
mean, i.e., ESSΛ, is 1341.
19
Hosted by The Berkeley Electronic Press
Design Stage
Eff. Bnd.
(u1,k, u2,k)
Eff. Bnd.
(z1,k, z2,k)
Futility Bnd. αs,k/0.05 ESS MSS
Simple
1-Stage
1 (2.2,2.2) (2.0,2.0) NA (0.5,0.5) 1818 1818
Optimized
1-Stage
1 (2.2,2.2) (1.9,2.0) NA (0.54,0.46) 1779 1779
1 (2.7,2.7) (2.5,2.5) (0,0,0,0) (1/8,1/8)
1528 2154
Simple 2 (2.6,2.6) (2.4,2.4) (0,0,0,0) (1/8,1/8)
Adaptive 3 (2.6,2.6) (2.3,2.3) (0,0,0,0) (1/8,1/8)
4 (2.5,2.5) (2.2,2.2) NA (1/8,1/8)
1 (2.5,3.2) (2.3,3.0) (0.1,0.6,0.7,0.8) (0.21,0.03)
1341 1917
Optimized 2 (2.5,3.3) (2.2,3.1) (-0.8,-1.6,-1.7,1.6) (0.17,0.01)
Adaptive 3 (2.7,2.6) (2.4,2.4) (-0.4,-3.2,-1.8,-0.8) (0.02,0.14)
4 (2.3,2.5) (2.1,2.2) NA (0.25,0.17)
Table 1: Design parameters for each of the four designs that are solutions to the SMART-
AV trial optimization problem defined in Section 6.1. The third and fourth columns are
the efficacy boundaries (u1,k, u2,k) and (z1,k, z2,k), respectively. For the adaptive designs, the
fifth column gives the futility boundaries (f1,1,k, f2,1,k, f1,2,k, f2,2,k), k = 1, 2, 3; NA indicates
not applicable, which is the case for the final stage of each design. The sixth column gives
the alpha allocations (α1,k, α2,k)/0.05 (rescaled by 0.05 so they sum to 1) for each stage
k = 1, . . . , K. The last two columns report the expected sample size (ESSΛ), and maximum
sample size (MSS) for each design.
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Table 2 gives the rejection probability for each null hypothesis under each scenario and
design. This represents power (for scenarios where the corresponding treatment effect is
positive) or Type I error (for scenarios where the corresponding treatment effect is zero,
indicated by bold numbers). It also gives the familywise Type I error rate (FWER) for each
design and scenario combination, which is always at most 0.05. For the optimized adaptive
design, the maximum familywise Type I error rate across the six scenarios is 0.047. Since
the futility boundaries are non-binding, the optimized adaptive design does not exhaust the
allowed familywise Type I error rate of 0.05. When no futility stopping is applied to the
optimized adaptive design, it exhausts the familywise Type I error rate, i.e., the familywise
Type I error rate is 0.05.
In scenario 1, where all null hypotheses are true, the Type I errors in columns 3-6 sum
to a value greater than the familywise Type I error rate (FWER). This is expected since
each of columns 3-6 gives the power to reject at least the corresponding null hypothesis, and
FWER is the probability of rejecting at least one true null hypothesis.
The power constraints are satisfied by each design, which follows from Table 2 since all the
non-boldface numbers (power) are at least 0.8. In scenario 6, all but the optimized adaptive
design have power close to 0.9 for each null hypothesis; the optimized adaptive design has
power closer to the required 0.8, which was achieved by a combination of higher futility
boundaries and an asymmetric alpha allocation. In this and other scenarios, the optimized
adaptive design saves resources (reflected in lower expected sample size) by achieving power
closer to what is required.
Figure 1 shows the distribution of sample sizes for each of the six scenarios for the
optimized adaptive design. Of the simulated trials conducted to evaluate the performance
of the optimized adaptive design, 96% had sample size smaller than the optimized 1-stage
design’s sample size of 1779.
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Rejection Probabilities
Subpopulation 1 Subpopulation 2 FWER
Design Scenario H1,1 H2,1 H1,2 H2,2
1 0.015 0.015 0.015 0.014 0.050
2 0.80 0.015 0.025 0.014 0.049
Simple 3 0.80 0.82 0.026 0.026 0.050
1-Stage 4 0.84 0.027 0.84 0.027 0.045
5 0.84 0.87 0.84 0.043 0.043
6 0.89 0.90 0.89 0.90 0
1 0.015 0.013 0.015 0.013 0.049
2 0.80 0.014 0.027 0.014 0.049
Optimized 3 0.80 0.80 0.027 0.023 0.049
1-Stage 4 0.84 0.026 0.84 0.026 0.044
5 0.84 0.86 0.84 0.044 0.044
6 0.89 0.89 0.88 0.89 0
1 0.014 0.014 0.014 0.013 0.049
2 0.80 0.016 0.024 0.016 0.050
Simple 3 0.80 0.85 0.022 0.011 0.032
Adaptive 4 0.83 0.024 0.83 0.024 0.042
5 0.83 0.88 0.83 0.039 0.039
6 0.88 0.90 0.89 0.90 0
1 0.019 0.0091 0.017 0.0090 0.047
2 0.80 0.0095 0.028 0.0093 0.044
Optimized 3 0.81 0.80 0.029 0.015 0.043
Adaptive 4 0.84 0.020 0.81 0.021 0.036
5 0.84 0.84 0.81 0.032 0.032
6 0.87 0.81 0.83 0.83 0
Table 2: Rejection probabilities for each scenario and null hypothesis for the four designs.
Boldface rejection probabilities correspond to Type I error and the non-bold rejection proba-
bilities correspond to power. The last column gives the familywise Type I error rate (FWER).
The rejection probability for each Ha,s is the probability of rejecting at least that null hy-
pothesis.
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Figure 1: Boxplots of sample size distributions for the optimized adaptive design under each
of the six scenarios. The horizontal dashed line indicates the sample size of the optimized
1-stage design.
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7 Software for Optimizing Our Adaptive Designs
Open-source software for optimizing over each of the aforementioned four design classes is
available at http://rosenblum.jhu.edu. The software allows the user to input their own opti-
mization problem by specifying the outcome type (continuous, binary, or time-to-event), the
distribution Λ (consisting of a discrete set of point masses), the power constraint scenarios
θ(1), . . . ,θ(M) and the required power for each null hypothesis under each such scenario. The
output is a reproducible, automatically generated report describing the performance of the
optimized design (computed using simulated annealing) from each class. The software has
a graphical user-interface that runs on a web-browser, whose purpose it to make the soft-
ware accessible to users without requiring knowledge of a specific statistical programming
language. The software is also available as an R package at
https://github.com/mrosenblum/AdaptiveDesignOptimizer
8 Discussion
We used simulated annealing to optimize the design parameters. A future research direction
is to investigate the impact of the starting values for the optimization problem as well as the
temperature parameter used by SA. Also, other optimization methods, e.g., gradient-based
methods, could be compared to SA.
Adjusting for prognostic baseline variables can lead to improved treatment effect estima-
tors compared to using the difference of sample mean estimator (Yang and Tsiatis, 2001).
Wald statistics based on such covariate-adjusted estimators could be used in place of the
z-statistics Za,s,k.
The alpha reallocation described in Section 4.2 can be generalized such that, when both
null hypotheses for subpopulation s are rejected, the alpha from subpopulation s gets real-
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located to the other subpopulation s′ across multiple stages (not just the final stage K). It
can be reallocated in any proportions to stages {k′, . . . , K}, where k′ is the first stage where
both null hypotheses for subpopulation s are rejected, as long as this is done according to
an algorithm that is prespecified (and not a function of the data except through k′). We
conjecture that this may help to reduce expected sample size by lowering efficacy boundaries
at earlier stages for one subpopulation when both null hypothesis are rejected for the other
subpopulation. The proof of Theorem 4.1 in Supplementary Web Appendix S.4 is given for
the aforementioned, generalized reallocation method.
The optimization problem described in Section 5 minimizes expected sample size subject
to power and Type I error constraints. An interesting alternative would be to minimize some
linear combination of maximum and expected sample size subject to power and Type I error
constraints.
An alternative approach to calculate the efficacy boundaries us,k is to replace (3) by
finding the smallest us,k ∈ [zs,k,∞) such that
P0
{
Za,s,k′ > us,k′ for at least one pair (a, k
′) with a ∈ {1, 2}, k′ ≤ k
}
≤
k∑
k′=1
αs,k′ . (4)
The main difference between the above display and (3) is that the former is in terms of
cumulative αs,k over the current and previous stages, while the latter considers each αs,k
separately. The two algorithms for computing us,k can differ if the efficacy boundary us,k
calculated using (3) does not fully exhaust the available αs,k, which can happen if the min-
imum us,k ∈ [zs,k,∞) satisfying (3) is at us,k = zs,k. In such a case, the boundaries at
subsequent stages computed using (4) could be lower than the corresponding boundaries
computed using (3), leading to more power. As discussed at the end of the proof of Theorem
4.1 in Supplementary Web Appendix S.4, using efficacy boundaries based on equation (4)
strongly controls the familywise Type I error rate.
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If both treatments in the SMART-AV trial were found to be superior to the standard
of care for a subpopulation, the investigators were further interested in testing if AV delay
optimized with the SmartDelay electrogram-based algorithm was non-inferior to echocar-
diographically optimized AV delay. In Section S.3 of the Supplementary Web Appendix,
we augment our class of adaptive enrichment designs by adding non-inferiority testing.
This is done in a way that does not reduce power for any of the original null hypothe-
ses Ha,s, a = 1, 2; s = 1, 2, and still guarantees strong control of the familywise Type I
error rate, asymptotically. For the optimized adaptive design, we calculated the power of
the non-inferiority tests with non-inferiority margin 0.7 in scenario δ(6) = (15, 15, 15, 15).
For each subpopulation, the power to reject the corresponding inferiority null hypothesis is
12%. Having low power for the non-inferiority test is not surprising, since non-inferiority
tests often require greater sample sizes than superiority tests. However, we were curious to
understand how low this power would be.
A limitation of the proposed design is that the simulated annealing algorithm is not guar-
anteed to find the global optimum, which is an open research problem. Another limitation
is that using an adaptive design results in larger maximum sample size compared to a single
stage design. Furthermore, implementing an adaptive design is more logistically complex
than implementing a simpler design. Another limitation of adaptive enrichment designs is
that they generally require the time from enrollment until the outcome is observed to be rel-
atively short compared to the enrollment period; otherwise, long times between enrollment
and measuring the outcome would prevent sufficient information from accruing in time to
make a useful decision about modifying enrollment.
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Supplementary Web Appendix
References to figures, tables, theorems and equations preceded by “S-” are internal to this
supplement; all other references refer to the main paper.
S.1 Distribution of Test Statistics
We derive the mean and the covariance matrix of the asymptotic joint distribution of the
test statistics. We make the assumptions stated in 3.
Theorem S.1.1. The joint distribution of (Z1,1,1, Z1,2,1, Z2,1,1, Z2,2,1, . . . , Z1,1,K , Z1,2,K , Z2,1,K , Z2,2,K)
is asymptotically normal with mean
E[Za,s,k] =
δa,s√
σ2a,s+σ
2
0,s∑k
k˜=1
∑n
k˜
i=1 I(Si,k˜=s)I(Ai,k˜=a)
=
µa,s − µ0,s√
σ2a,s+σ
2
0,s∑k
k˜=1
∑n
k˜
i=1 I(Si,k˜=s)I(Ai,k˜=a)
.
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and covariance matrix with
Cov(Za,s,k, Za,s,k) = 1
Cov(Za,s,k, Za,s,k′) =
√√√√∑min(k,k′)k˜=1 ns,k˜∑max(k,k′)
k˜=1
ns,k˜
Cov(Za,s,k, Za′,s,k) =
σ20,s√
(σ2a,s + σ
2
0,s)(σ
2
a′,s + σ
2
0,s)
Cov(Za,s,k, Za′,s,k′) =
σ20,s√
(σ2a,s + σ
2
0,s)(σ
2
a′,s + σ
2
0,s)
√√√√∑min(k,k′)k˜=1 ns,k˜∑max(k,k′)
k˜=1
ns,k˜
Cov(Za,1,k, Za′,2,k′) = 0 for all other combinations of (a, k, a
′, k′)
Proof. Basic calculations show that E[Za,s,k] has the desired form. When deriving the co-
variance matrix, we will repeatedly use the property that for a given a ∈ {0, 1, 2},
Cov
 1∑k
k˜=1 ns,k˜
k∑
k˜=1
nk˜∑
i=1
I(Ai,k˜ = a)I(Si,k˜ = s)Yi,k˜,
1∑k′
k˜=1 ns,k˜
k′∑
k˜=1
nk˜∑
i=1
I(Ai,k˜ = a)I(Si,k˜ = s)Yi,k˜

=
1∑k
k˜=1 ns,k˜
1∑k′
a=1 ns,k˜
min(k,k′)∑
k˜=1
nk˜∑
i=1
I(Ai,k˜ = a)I(Si,k˜ = s)σ
2
a,s
=
σ2a,s
max(
∑k
k˜=1 ns,k˜,
∑k′
k˜=1 ns,k˜)
2
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We have
Cov(Za,s,k, Za,s,k)
=
1√
σ2a,s+σ
2
0,s∑k
k˜=1
ns,k˜
σ2a,s+σ
2
0,s∑k
a=1 ns,k˜
1∑k
k˜=1 ns,k˜
1∑k
k˜=1 ns,k˜
k∑
k˜=1
nk˜∑
i=1
I(Si,k˜ = s)[I(Ai,k˜ = a)σ
2
a,s + I(Ai,k˜ = 0)σ
2
0,s]
= 1.
If k = k′, s = s′ and l 6= a′
Cov(Za,s,k, Za′,s,k)
=
1√
σ2a,s+σ
2
0,s∑k
k˜=1
ns,k˜
σ2
a′,s+σ
2
0,s∑k
k˜=1
ns,k˜
1∑k
k˜=1 ns,k˜
1∑k
k˜=1 ns,k˜
k∑
k˜=1
nk˜∑
i=1
I(Si,k˜ = s)I(Ai,k˜ = 0)σ
2
0,s
=
1√
σ2a,s+σ
2
0,s∑k
k˜=1
ns,k˜
σ2
a′,s+σ
2
0,s∑k
k˜=1
ns,k˜
σ20,s∑k
k˜=1 ns,k˜
=
σ20,s√
(σ2a,s + σ
2
0,s)(σ
2
a′,s + σ
2
0,s)
.
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If k 6= k′, s = s′, and a = a′
Cov(Za,s,k, Za,s,k′)
=
1√
σ2a,s+σ
2
0,s∑k
k˜=1
ns,k˜
σ2a,s+σ
2
0,s∑k′
k˜=1
ns,k˜
1∑k
k˜=1 ns,k˜
1∑k′
k˜=1 ns,k˜
min(k,k′)∑
k˜=1
nk˜∑
i=1
I(Si,k˜ = s)[I(Ai,k˜ = a)σ
2
a,s + I(Ai,k˜ = 0)σ
2
0,s]
=
1√
σ2a,s+σ
2
0,s∑k
k˜=1
ns,k˜
σ2a,s+σ
2
0,s∑k′
k˜=1
ns,k˜
σ2a,s + σ
2
0,s
max(
∑k
k˜=1 ns,k˜,
∑k′
k˜=1 ns,k˜)
=
√√√√min(∑kk˜=1 ns,k˜,∑k′k˜=1 ns,k˜)
max(
∑k
k˜=1 ns,k˜,
∑k′
k˜=1 ns,k˜)
.
If k 6= k′, l 6= a′ and s = s′
Cov(Za,s,k, Za′,s,k′)
=
1√
σ2a,s+σ
2
0,s∑k
k˜=1
ns,k˜
σ2
a′,s+σ
2
0,s∑k′
k˜=1
ns,k˜
1∑k
k˜=1 ns,k˜
1∑k′
k˜=1 ns,k˜
min(k,k′)∑
a=1
nk˜∑
i=1
I(Si,k˜ = s)I(Ai,k˜ = 0)σ
2
0,s
=
√√√√min(∑kk˜=1 ns,k˜,∑k′k˜=1 ns,k˜)
max(
∑k
k˜=1 ns,k˜,
∑k′
k˜=1 ns,k˜)
σ20,s√
(σ20,s + σ
2
a,s)(σ
2
0,s + σ
2
a′,s)
.
Note that if all variances are assumed equal, then
σ20,s√
(σ20,s+σ
2
a,s)(σ
2
0,s+σ
2
a′,s)
= 1
2
.
S.2 Starting Values for Simulated Annealing Searches
The simulated annealing algorithm requires initial values to be input for all design parameters
that it optimizes. These are given here.
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For design class two, we used α1,1 = α2,1 = 0.025.
For design class 4 with K = 4, initial values were the following: equal alpha allocations for
all stages and subpopulation combinations (i.e. αs,k = 0.05/8 for s = 1, 2, k = 1, 2, 3, 4), all
futility boundaries set to −1, the timing of the interim analysis is set to when 10%, 33%, 67%,
and 100% of the primary outcomes are observed. For each of design classes 1-4, we initialized
the maximum sample size n to be 2250, 1890, 1950, 1950, respectively. The first of these was
selected based on a quick initial search over n to determine roughly what magnitude is
required to satisfy the power constraints for design class one; values of n for the subsequent
design classes were based on the optimal results for the previous classes. For example,
for classes 3 and 4, the initial value n = 1950 was selected by slightly increasing the value
n = 1779 that resulted from optimizing over design class two; this was based on our intuition
that larger values of n are typically required in order to achieve a reduction in the expected
sample size, when comparing single stage versus multiple stage designs.
For design class four with K = 2 or K = 3 stages, the initial values were the same as
described above for K = 4 with the following exceptions: for K = 2 the analysis times were
started at 10% and 100% of outcomes observed; for K = 3 the analysis times were started
at 30%, 50%, and 100% of outcomes observed.
S.3 Test for Non-inferiority Following Superiority of
Both Treatments in a Subpopulation
An added feature of the SMART-AV trial design is that if both treatments are found to
be superior to the control for a subpopulation, then a non-inferiority test is conducted to
compare the treatments (Stein et al., 2010). This section incorporates an additional non-
inferiority test into our adaptive enrichment designs, while maintaining strong control of the
familywise Type I error rate.
5
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For subpopulation s and for a prespecified non-inferiority margin τ ∈ (0, 1], interest
lies in evaluating if treatment a = 1 preserves more than 100 ∗ τ percent of the benefit of
treatment a = 2 compared to the control a = 0. An advantage of this approach is that,
since non-inferiority is tested only if superiority of both treatments compared to the control
has already been established, the treatment effect comparing a = 2 versus control a = 0
has already been assessed within the trial, obviating the need to rely on historical data to
estimate this treatment effect. The non-inferiority test for subpopulation s is only performed
if (i) accrual continues for both treatments through stage K for that subpopulation and (ii)
both H1,s, H2,s are rejected using the original efficacy thresholds {us,k, zs,k : s = 1, 2; k ≤ K}
without reallocation of alpha from the other subpopulation.
Since the non-inferiority hypothesis test is only conducted for subpopulation s after the
null hypotheses H1,s, H2,s have been rejected, we assume below that µa,s − µ0,s > 0 for
each a ∈ {1, 2}. The inferiority null hypothesis for subpopulation s is defined as H(Inf)s :
µ1,s − µ0,s ≤ τ(µ2,s − µ0,s) or equivalently H(Inf)s : µ1,s − τµ2,s − (1 − τ)µ0,s ≤ 0. For
subpopulation s, define the standardized statistic for testing H
(Inf)
s as
Z(Inf)s =
{
Y¯1,s,K − τ Y¯2,s,K − (1− τ)Y¯0,s,K
}{ σ21,s∑K
k=1 n1,s,k
+ τ 2
σ22,s∑K
k=1 n2,s,k
+ (1− τ)2 σ
2
0,s∑K
k=1 n0,s,k
}−1/2
.
Under H
(Inf)
s , the test statistic is asymptotically normally distributed with unit variance
and mean at most 0 (Pigeot et al., 2003).
For each subpopulation s ∈ {1, 2}, we reject H(Inf)s if Z(Inf)s > Φ−1(1 − α/2), where
Φ−1(1 − α/2) is the 1 − α/2 quantile of the standard normal distribution. This ensures
that the familywise Type I error rate for the optimized adaptive design (considering all 4
superiority null hypotheses Ha,s and the 2 non-inferiority null hypotheses) is at most α.
Implementation requires specifying the non-inferiority margin τ . That is, specifying how
much treatment effect reduction for treatment a = 1 compared to a = 2 is acceptable. This
6
Hosted by The Berkeley Electronic Press
choice is a clinical judgment and depends on what the benefits of treatment a = 1 compared
to a = 2 are (e.g., in term of safety, side effects, or cost).
The correlation between the test statistics for non-inferiority and test for superiority in
subpopulation s = 1, 2 is given by
Cov(Z(Inf)s , Z1,s,k) =
σ21,s∑K
k=1 n1,s,k
+
(1−τ)σ20,s∑K
k=1 n0,s,k√
σ21,s+σ
2
0,s∑K
k=1 n1,s,k
√
σ21,s∑K
k=1 n1,s,k
+ τ 2
σ22,s∑K
k=1 n2,s,k
+ (1− τ)2 σ20,s∑K
k=1 n0,s,k
Cov(Z(Inf)s , Z2,s,k) =
− τσ22,s∑K
k=1 n2,s,k
+
(1−τ)σ20,s∑K
k=1 n0,s,k√
σ22,s+σ
2
0,s∑K
k=1 n2,s,k
√
σ21,s∑K
k=1 n1,s,k
+ τ 2
σ22,s∑K
k=1 n2,s,k
+ (1− τ)2 σ20,s∑K
k=1 n0,s,k
.
The mean of the test statistics Z
(Inf)
s , s = 1, 2 is given by
E[Z(Inf)s ] =
µ1,s − τµ2,s − (1− τ)µ0,s√
σ21,s
N1,s
+ τ 2
σ22,s
N2,s
+ (1− τ)2 σ20,s
N0,s
,
S.4 Proof of Theorem 4.1
For convenience of notation below, define z˜s,k and u˜s,k to equal zs,k and us,k, respectively,
whenever no alpha reallocation is used.
Define a closed testing procedure using the following local tests:
• Test of elementary null hypothesis Ha,s: reject if Za,s,k > z˜s,k for at least one k ∈
{1, . . . , K}.
• Intersection test of H1,s ∩ H2,s, s ∈ {1, 2}: reject if Za,s,k > u˜s,k for at least one pair
(a, k), a ∈ {1, 2}, k ∈ {1, . . . , K}.
• For s 6= s′, s, s′ ∈ {1, 2}, any a, a′ ∈ {1, 2}, intersection test of Ha,s ∩ Ha′,s′ : reject if
Za,s,k > zs,k or Za′,s′,k > zs′,k for at least one k ∈ {1, . . . , K}.
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• For s 6= s′, s, s′ ∈ {1, 2}, any a′ ∈ {1, 2}, intersection test of H1,s ∩H2,s ∩Ha′,s′ : reject
if Za,s,k > us,k for at least one pair (a, k), a ∈ {1, 2}, k ∈ {1, . . . , K} or if Za′,s′,k > zs′,k
for some k ∈ {1, . . . , K}.
• Intersection test of all 4 null hypotheses: reject if Za,s,k > us,k for at least one triple
(a, s, k), a, s ∈ {1, 2}, k ∈ {1, . . . , K}.
For a set A the intersection hypothesis corresponding to A can only by rejected at stage k if
all intersection hypothesis that include A are rejected at or before stage k.
Now we show that for a fixed a, s ∈ {1, 2} DADAPT rejects Ha,s if and only if the closed
testing procedure rejects every intersection hypothesis involving Ha,s. Without loss of gen-
erality we assume (a, s) = (1, 1).
If DADAPT rejects H1,1, at least one of the following two statements is true: 1) there exists
a k ∈ {1, . . . , K} s.t. Z1,1,k > u˜1,k; 2) there exits a k ∈ {1, . . . , K} such that Z1,1,k > z˜1,k
and Z2,1,m > u˜1,m for some m ≤ k.
First we assume that statement 1) is true and show that all intersection hypothesis
involving H1,1 are rejected. Let k
∗ be the first stage satisfying Z1,1,k∗ > u˜1,k∗ .
• The intersection test H1,1 ∩ H2,1 ∩ H1,2 ∩ H2,2: If alpha reallocation is done from
population 1 to population 2 before or at stage k∗, Za,1,k > u1,k for at least one
(a, k), a ∈ {1, 2}, k ∈ {1, . . . , k∗} pair. If alpha reallocation is done from population
2 to population 1 before or at stage k∗, Za,2,k > u2,k for at least one pair (a, k), a ∈
{1, 2}, k ∈ {1, . . . , k∗}. If no reallocation is done before or at stage k∗, u˜s,k = us,k for
all combinations of (s, k), s ∈ {1, 2}, k ∈ {1, . . . , k∗} and by 1) Z1,1,k∗ > u˜1,k∗ = us,k∗ .
• The intersection test H1,1 ∩ H2,1 ∩ Ha′,2 for a′ = 1, 2. If alpha reallocation is done
from population 1 to population 2 before or at stage k∗, Za,1,k > u1,k for at least one
(a, k), a ∈ {1, 2}, k ∈ {1, . . . , k∗} pair. If alpha reallocation is done from population
2 to population 1 before or at stage k∗, Za′,2,k > z2,k for at least one k ∈ {1, . . . , k∗}.
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If no reallocation is done before or at stage k∗, u˜s,k = us,k for all combinations of
(s, k) : s ∈ {1, 2}, k ∈ {1, . . . , k∗}. Hence, if 1) holds Z1,1,k∗ > u˜1,k∗ = u1,k∗ .
• The intersection test H1,2 ∩H2,2 ∩H1,1: If alpha reallocation is done from population
1 to population 2 before or at stage k∗, Z1,1,k > z1,k for at least one k ∈ {1, . . . , k∗}.
If alpha reallocation is done from population 2 to population 1 before or at stage k∗,
Za,2,k > u2,k for at least one pair (a, k), a ∈ {1, 2}, k ∈ {1, . . . , k∗}. If no reallocation
is done before or at stage k∗, z˜s,k = zs,k and u˜s,k = us,k for all combinations of (s, k) :
s ∈ {1, 2}, k ∈ {1, . . . , k∗}. As u˜1,k ≥ z˜1,k for all k ∈ {1, . . . , K}, it follows that if 1)
holds Z1,1,k∗ > u˜1,k∗ ≥ z˜1,k∗ = z1,k∗ .
• The intersection test H1,1 ∩ Ha′,2 for a′ ∈ {1, 2}: If alpha reallocation is done from
population 1 to population 2 before or at stage k∗, Z1,1,k > z1,k for at least one k ∈
{1, . . . , k∗}. If alpha reallocation is done from population 2 to population 1 before or
at stage k∗, Za′,2,k > z2,k for at least one k ∈ {1, . . . , k∗}. If no reallocation is done
before or at stage k∗, u˜1,k∗ ≥ z˜1,k∗ = z1,k∗ . Hence, from 1) Z1,1,k∗ > z1,k.
• The intersection test H1,1 ∩H2,1: Follows directly from 1).
• The intersection test H1,1: Follows directly from 1) and u˜1,k∗ ≥ z˜1,k∗ .
Now assume that statement 2) is correct. Let k∗ be the first stage satisfying Z1,1,k∗ > z˜1,k∗
and m∗ be the first stage satisfying Z2,1,m∗ > u˜1,m∗ . By assumption 2) m∗ ≤ k∗.
• The intersection test H1,1 ∩ H2,1 ∩ H1,2 ∩ H2,2: If alpha reallocation is done from
population 1 to population 2 before or at stage m∗, Za,1,k > u1,k for at least one
(a, k), a ∈ {1, 2}, k ∈ {1, . . . ,m∗} pair. If alpha reallocation is done from population
2 to population 1 before or at stage m∗, Za,2,k > u2,k for at least one pair (a, k), a ∈
{1, 2}, k ∈ {1, . . . ,m∗}. If no reallocation is done before or at stage m∗, u˜1,m∗ = u1,m∗
and by 2) Z2,1,m∗ > u˜1,m∗ = u1,m∗ .
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• The intersection test H1,1 ∩ H2,1 ∩ Ha′,2 for a′ = 1, 2. If alpha reallocation is done
from population 1 to population 2 before or at stage m∗, Za,1,k > u1,k for at least one
(a, k), a ∈ {1, 2}, k ∈ {1, . . . ,m∗} pair. If alpha reallocation is done from population 2
to population 1 before or at stage m∗, Za′,2,k > z2,k for at least one k ∈ {1, . . . ,m∗}. If
no reallocation is done before or at stage m∗, u˜s,m∗ = us,m∗ for s ∈ {1, 2}. Hence, if 2)
holds Z2,1,m∗ > u˜1,m∗ = u1,m∗ .
• The intersection test H1,2 ∩H2,2 ∩H1,1: If alpha reallocation is done from population
1 to population 2 before or at stage k∗, Z1,1,k > z1,k for at least one k ∈ {1, . . . , k∗}.
If alpha reallocation is done from population 2 to population 1 before or at stage k∗,
Za,2,k > u2,k for at least one pair (a, k), a ∈ {1, 2}, k ∈ {1, . . . , k∗}. If no reallocation is
done, z˜s,k∗ = zs,k∗ and by 2) Z1,1,k∗ > z˜1,k∗ = z1,k∗ .
• The intersection test H1,1 ∩ Ha′,2 for a′ ∈ {1, 2}: If alpha reallocation is done from
population 1 to population 2 before or at stage k∗, Z1,1,k > z1,k for at least one k ∈
{1, . . . , k∗}. If alpha reallocation is done from population 2 to population 1 before or
at stage k∗, Za′,2,k > z2,k for at least one k ∈ {1, . . . , k∗}. If no reallocation is done
before or at stage k∗, z˜1,k∗ = z1,k∗ . Hence, it follows from 2) that Z1,1,k∗ > z1,k∗ .
• The intersection test H1,1 ∩H2,1: Follows directly from 2).
• The intersection test H1,1: Follows directly from 2).
This shows that if DADAPT rejects H1,1, then all intersection tests involving H1,1 are also
rejected.
If H1,1 ∩H1,2 is rejected at stage k and ∩{(a,s)=(1,1)}Ha,s is rejected at stage k′ ≥ k then
DADAPT rejectes H1,1. This completes the proof that for a fixed a, s ∈ {1, 2}, DADAPT rejects
Ha,s if and only if the closed testing procedure rejects every intersection hypothesis involving
Ha,s.
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Now we want to show that all intersection tests control the familywise Type I error rate.
• Elementary null hypothesis Ha,s: For a given a, s ∈ {1, 2}, the probability of making a
Type I error under the null Ha,s is bounded above by
K∑
k=1
P (Za,s,k′ ≤ z˜s,k′ for all k′ < k,Za,s,k > z˜s,k) ≤
K∑
k=1
α1,k +
K∑
k=1
α2,k = α
where the inequality follows from the construction of the efficacy boundaries z˜s,k.
• Intersection of H1,s ∩ H2,s: Both H1,s and H2,s are true. The probability of a Type I
error in subpopulation s ∈ {1, 2} is bounded above by
K∑
k=1
P (max(Z1,s,k′ , Z2,s,k′) ≤ u˜s,k′ for all k′ < k,max(Z1,s,k, Z2,s,k) > u˜s,k)
≤
K∑
k=1
α1,k +
K∑
k=1
α2,k = α.
Here, the inequality follows from the construction of the efficacy boundaries u˜s,k.
• Intersection test of Ha,s ∩Ha′,s′ s 6= s′, with s, s′ ∈ {1, 2} and a, a′ ∈ {1, 2}. Under the
null of Ha,s and Ha′,s′ both being true, the Type I error is bounded above by
K∑
k=1
P (Za,s,k′ ≤ zs,k′ for all k′ < k,Za,s,k > zs,k)
+
K∑
k=1
P (Za′,s′,k′ ≤ zs′,k′ for all k′ < k,Za′,s′,k > zs′,k)
≤
K∑
k=1
αs,k +
K∑
k=1
αs′,k = α,
where the inequality follows from the construction of the efficacy boundaries zs,k
• For s 6= s′ with s, s′ ∈ {1, 2} and a′ ∈ {1, 2}, intersection test of H1,s ∩ H2,s ∩ Ha′,s′ :
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Under the null of all three hypothesis in the test being true, the Type I error is bounded
from above by
K∑
k=1
P (max(Z1,s,k′ , Z2,s,k′) ≤ us,k′ for all k′ < k,max(Z1,s,k, Z2,s,k) > us,k)
+
K∑
k=1
P (Za′,s′,k′ ≤ zs′,k′ for all k′ < k,Za′,s′,k > zs′,k)
≤
2∑
s=1
K∑
k=1
αs,k = α,
where the inequality follows from the construction of the efficacy boundaries (zs,k, us,k).
• Intersection test of all 4 null hypotheses: Under the null of no treatment effect in any
subpopulation and treatment combination, the Type I error is bounded above by
2∑
s=1
K∑
k=1
P (max(Z1,s,k′ , Z2,s,k′) ≤ us,k′ for all k′ < k,max(Z1,s,k, Z2,s,k) > us,k)
≤
2∑
s=1
K∑
k=1
αs,k = α,
where the inequality follows from the construction of the efficacy boundaries us,k.
As all intersection test have Type I error rate at most α, the closed testing principle implies
that DADAPT controls the familywise Type I error rate at a level α.
In Section 8, an alternative way of calculating efficacy boundaries us,K , s = 1, 2, k =
1, . . . , K is presented. It follows from the construction of the efficacy boundaries (see equation
(4)) that all intersection tests using these efficacy boundaries control the familywise Type I
error rate. Hence, DADAPT implemented using efficacy boundaries calculated using equation
(4) strongly control the familywise Type I error.
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